Published in:
01-02-2020 | Levothyroxine | Letter to the Editor
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
Author:
Patrick Nicolas
Published in:
Clinical Pharmacokinetics
|
Issue 2/2020
Login to get access
Excerpt
In their article, Concordet et al. [
1] deliver a second set of criticisms against the study by Gottwald-Hostalek et al. [
2]. In this letter, I would like to challenge this additional argumentation that has already reboosted sensational headlines about the French ‘Levothyrox
® scandal’. …